Extracellular matrix turnover biomarkers reflect pharmacodynamic effects and treatment response of adalimumab in patients with axial spondyloarthritis—results from two randomized controlled trials

Extracellular matrix turnover biomarkers reflect pharmacodynamic effects and treatment response of adalimumab in patients with axial spondyloarthritis—results from two randomized controlled trials

Abstract Objective To investigate if extracellular matrix (ECM) blood-based biomarkers reflect the pharmacodynamic effect and response to TNF-α inhibitor therapy (adalimumab, ADA), in patients with axial spondyloarthritis (axSpA). Methods We investigated ECM biomarkers in two randomized, double-blin...

Full description

Bibliographic Details
Main Authors: Helena Port, Signe Holm Nielsen, Peder Frederiksen, Sofie Falkenløve Madsen, Anne-Christine Bay-Jensen, Inge Juul Sørensen, Bente Jensen, Anne Gitte Loft, Ole Rintek Madsen, Mikkel Østergaard, Susanne Juhl Pedersen
Format: Article
Language:English
Published: BMC 2023-08-01
Series:Arthritis Research & Therapy
Subjects:
Axial spondyloarthritis
Extracellular matrix
Biomarkers
Adalimumab
Online Access:https://doi.org/10.1186/s13075-023-03132-5

Internet

https://doi.org/10.1186/s13075-023-03132-5

Similar Items